Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data ; volume:21 ; number:1 ; day:2 ; month:5 ; year:2019 ; pages:1-11 ; date:12.2019
Arthritis Research & Therapy ; 21, Heft 1 (2.5.2019), 1-11, 12.2019
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Deodhar, A.
Mease, P. J.
McInnes, I. B.
Baraliakos, X.
Reich, K.
Blauvelt, A.
Leonardi, C.
Porter, B.
Das Gupta, A.
Widmer, A.
Pricop, L.
Fox, T.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-019-1882-2
- URN
-
urn:nbn:de:101:1-2019052122102741132339
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-14T10:57:47+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Deodhar, A.
- Mease, P. J.
- McInnes, I. B.
- Baraliakos, X.
- Reich, K.
- Blauvelt, A.
- Leonardi, C.
- Porter, B.
- Das Gupta, A.
- Widmer, A.
- Pricop, L.
- Fox, T.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study